Your browser is no longer supported. Please, upgrade your browser.
Settings
ARVN Arvinas, Inc. daily Stock Chart
ARVN [NASD]
Arvinas, Inc.
Index- P/E- EPS (ttm)-2.06 Insider Own0.60% Shs Outstand75.27M Perf Week0.05%
Market Cap2.89B Forward P/E- EPS next Y-2.41 Insider Trans146.14% Shs Float70.27M Perf Month71.44%
Income-65.30M PEG- EPS next Q-0.53 Inst Own69.10% Short Float3.68% Perf Quarter65.46%
Sales41.50M P/S69.68 EPS this Y-736.70% Inst Trans1.68% Short Ratio7.25 Perf Half Y89.63%
Book/sh4.10 P/B9.37 EPS next Y-21.10% ROA-34.10% Target Price35.67 Perf Year143.32%
Cash/sh2.53 P/C15.18 EPS next 5Y- ROE-50.70% 52W Range10.19 - 39.33 Perf YTD198.99%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-2.32% Beta-
Dividend %- Quick Ratio6.80 Sales past 5Y- Gross Margin- 52W Low277.04% ATR1.84
Employees103 Current Ratio6.80 Sales Q/Q785.30% Oper. Margin- RSI (14)79.38 Volatility4.99% 5.91%
OptionableYes Debt/Eq0.01 EPS Q/Q86.60% Profit Margin- Rel Volume0.77 Prev Close37.76
ShortableYes LT Debt/Eq0.01 EarningsNov 04 Payout- Avg Volume356.64K Price38.42
Recom1.90 SMA2017.22% SMA5055.70% SMA20070.42% Volume271,840 Change1.75%
Nov-25-19Initiated Guggenheim Buy $50
Oct-24-19Upgrade Goldman Neutral → Buy $23 → $38
Sep-25-19Initiated Wedbush Outperform $38
Sep-12-19Initiated BMO Capital Markets Outperform
Aug-06-19Initiated Cantor Fitzgerald Overweight $42
Jun-05-19Downgrade Citigroup Buy → Neutral $21 → $22
Apr-12-19Initiated Evercore ISI Outperform
Oct-22-18Initiated Piper Jaffray Overweight $23
Oct-22-18Initiated Goldman Neutral $17
Oct-22-18Initiated Citigroup Buy $21
Nov-27-19 07:30AM  Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire +8.63%
Nov-26-19 08:06AM  The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug Benzinga
Nov-25-19 11:40AM  Arvinas TPD Therapies Have Great Potential, Guggenheim Says In Bullish Initiation Benzinga
Nov-21-19 07:30AM  Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors GlobeNewswire
Nov-17-19 12:44PM  Notable Insider Buys In The Past Week: Arvinas, Dropbox, Trinity Benzinga
Nov-06-19 09:40PM  Arvinas, Inc. Announces Pricing of Public Offering of Common Stock GlobeNewswire
04:01PM  Arvinas, Inc. Announces Proposed Offering of Common Stock GlobeNewswire
Nov-05-19 09:00AM  Arvinas, Inc. (ARVN) Upgraded to Strong Buy: Here's Why Zacks +5.11%
Nov-04-19 05:00PM  Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Oct-31-19 11:50AM  Goldman Sachs: 3 Standout Healthcare Stocks That Could Double TipRanks
Oct-30-19 09:36AM  Hedge Funds Are Selling Arvinas, Inc. (ARVN) Insider Monkey
Oct-23-19 07:54AM  The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data Benzinga +14.64%
06:30AM  Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders GlobeNewswire
Oct-20-19 08:08AM  The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict Benzinga
Oct-19-19 09:02AM  Have Insiders Been Buying Arvinas, Inc. (NASDAQ:ARVN) Shares This Year? Simply Wall St.
Oct-17-19 07:00AM  Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit GlobeNewswire
Oct-02-19 07:00AM  Arvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological Disorders GlobeNewswire
Oct-01-19 02:54PM  Bayer funnels $55M into new startup with Triangle touchpoint American City Business Journals -7.10%
04:00AM  Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio GlobeNewswire
Sep-25-19 02:44PM  Wedbush Starts Arvinas At Outperform, Says Lead Assets Could Have Successful Trials Benzinga
Aug-27-19 07:00AM  Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein Degrader GlobeNewswire
Aug-16-19 12:46PM  David Swensen Sells DocuSign in 2nd Quarter GuruFocus.com
Aug-07-19 07:00AM  Arvinas To Present at the Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-05-19 07:00AM  Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire -7.86%
Jul-31-19 01:48PM  Steven Cohen Charges Into Chiasma GuruFocus.com
Jul-29-19 07:00AM  Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer GlobeNewswire
Jul-25-19 07:00AM  Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk GlobeNewswire +7.28%
Jul-18-19 07:00AM  Arvinas to Present Preclinical Tau-Directed PROTAC® Protein Degrader Data at Alzheimer's Association International Conference GlobeNewswire
Jun-27-19 06:54AM  Will Arvinas Continue to Surge Higher? Zacks
Jun-26-19 06:28PM  Is Arvinas, Inc. (ARVN) A Good Stock To Buy? Insider Monkey
Jun-25-19 07:00AM  Arvinas Receives Authorization to Proceed for ARV-471, a PROTAC® Protein Degrader to Treat Patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer GlobeNewswire
Jun-20-19 08:30AM  Arvinas to Present at the BMO Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-06-19 07:00AM  Arvinas to Present at the Goldman Sachs 40th Annual Global Healthcare Conference GlobeNewswire
Jun-04-19 07:00AM  Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants PR Newswire +9.68%
07:00AM  Bayer and Arvinas to Collaborate on Human PROTAC® Therapies and Launch a Separate Joint Venture to Develop Agricultural PROTAC® Applications GlobeNewswire
May-29-19 07:00AM  Arvinas Receives Fast Track Designation for its Targeted Protein Degrader ARV-110 as a Treatment for Men with Metastatic Castration-Resistant Prostate Cancer GlobeNewswire +5.11%
May-11-19 01:30PM  Did Hedge Funds Drop The Ball On Arvinas, Inc. (ARVN) ? Insider Monkey
May-08-19 07:00AM  Arvinas Reports First Quarter Financial Results and Provides Corporate Update GlobeNewswire +5.79%
Apr-02-19 07:00AM  Arvinas Strengthens Management Team with Internal Appointments of Andy Crew, Ph.D. as Chief Technology Officer and Ian Taylor, Ph.D. as Chief Scientific Officer GlobeNewswire +8.33%
Mar-26-19 07:00AM  Arvinas Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Mar-25-19 07:00AM  Arvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC Protein Degrader, ARV-110 GlobeNewswire
Mar-16-19 09:16AM  Did Arvinas Holding Company, LLC (NASDAQ:ARVN) Insiders Buy Up More Shares? Simply Wall St.
Feb-07-19 04:30PM  Arvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium GlobeNewswire
Feb-01-19 12:08PM  Protein Degradation: Finally, A Way To Treat 'Undruggable' Diseases? Investor's Business Daily
Jan-04-19 05:00PM  Arvinas Receives Authorization to Proceed for its IND Application for PROTAC Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer GlobeNewswire +6.35%
Dec-07-18 07:00PM  Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS) GlobeNewswire +5.07%
Nov-20-18 06:00AM  Arvinas To Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Oct-23-18 07:30AM  Arvinas to Present at Two Protein Degradation Conferences GlobeNewswire
Oct-03-18 08:15PM  Arvinas Inc (ARVN) President and CEO John G Houston Bought $480,000 of Shares GuruFocus.com +5.67%
Sep-27-18 10:42AM  Arvin's stock soars in its public debut, after upsized IPO priced at top of expected range MarketWatch
06:49AM  [$$] Biotech Arvinas Prices Upsized IPO at High End of Range The Wall Street Journal
Sep-26-18 08:06PM  Arvinas Announces Pricing of Initial Public Offering GlobeNewswire
Sep-22-18 04:15PM  The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers Benzinga
Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has a collaboration with Bayer AG to develop novel proteolysis-targeting chimera candidates for humans and plants. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cassidy Sean AChief Financial OfficerNov 19Sale32.0010,000320,000159,115Nov 21 05:45 PM
Taylor IanChief Scientific OfficerNov 13Sale28.0010,000280,00055,496Nov 15 05:13 PM
Ratcliffe LiamDirectorNov 12Buy22.00680,00014,960,000680,000Nov 14 04:23 PM